Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Six-year outcomes of robot-assisted radical prostatectomy versus volumetric modulated arc therapy for localized prostate cancer: A propensity score-matched analysis.
Noda M, Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, Kamei J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Yamashita H, Nakagawa K, Abe O, Fukuhara H, Kume H. Noda M, et al. Among authors: sato y. Strahlenther Onkol. 2024 Aug;200(8):676-683. doi: 10.1007/s00066-023-02192-5. Epub 2024 Jan 5. Strahlenther Onkol. 2024. PMID: 38180494 Free PMC article.
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma.
Sugimoto K, Taguchi S, Kishitani K, Kawai T, Masuda K, Nakamura Y, Kinjo M, Tambo M, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Fukuhara H, Kume H. Sugimoto K, et al. Among authors: sato y. BMC Urol. 2022 Nov 9;22(1):177. doi: 10.1186/s12894-022-01139-9. BMC Urol. 2022. PMID: 36352389 Free PMC article.
Subclassification of pT3 upper tract urothelial carcinoma: a multicenter retrospective study.
Yamada Y, Nakagawa T, Miyakawa J, Kawai T, Taguchi S, Tabata M, Kaneko T, Ishikawa A, Miyazaki H, Kondo Y, Matsumoto A, Naito A, Hikatsu M, Fujii Y, Akiyama Y, Yamada Y, Sato Y, Nomiya A, Yamada D, Murata T, Suzuki M, Enomoto Y, Nishimatsu H, Takeuchi T, Tanaka Y, Kume H. Yamada Y, et al. Among authors: sato y. World J Urol. 2023 Mar;41(3):767-776. doi: 10.1007/s00345-023-04300-7. Epub 2023 Feb 4. World J Urol. 2023. PMID: 36739339
Deep Learning Models for Cystoscopic Recognition of Hunner Lesion in Interstitial Cystitis.
Iwaki T, Akiyama Y, Nosato H, Kinjo M, Niimi A, Taguchi S, Yamada Y, Sato Y, Kawai T, Yamada D, Sakanashi H, Kume H, Homma Y, Fukuhara H. Iwaki T, et al. Among authors: sato y. Eur Urol Open Sci. 2023 Jan 26;49:44-50. doi: 10.1016/j.euros.2022.12.012. eCollection 2023 Mar. Eur Urol Open Sci. 2023. PMID: 36874607 Free PMC article.
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Taguchi S, et al. Among authors: sato y. Immunotherapy. 2023 Aug;15(11):827-837. doi: 10.2217/imt-2023-0028. Epub 2023 May 16. Immunotherapy. 2023. PMID: 37191002
14,336 results
You have reached the last available page of results. Please see the User Guide for more information.